"Cytochrome P-450 CYP3A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.
| Descriptor ID |
D051544
|
| MeSH Number(s) |
D08.244.453.860.500 D08.811.682.662.582.353 D08.811.682.690.708.170.495.500 D12.776.422.220.453.860.500
|
| Concept/Terms |
Cytochrome P-450 CYP3A- Cytochrome P-450 CYP3A
- Cytochrome P 450 CYP3A
- P-450 CYP3A, Cytochrome
- Cytochrome P-450IIIA
- Cytochrome P 450IIIA
- P-450IIIA, Cytochrome
- Erythromycin N-Demethylase
- Erythromycin N Demethylase
- N-Demethylase, Erythromycin
- CYP3A
- Cytochrome P450 3A
- P450 3A, Cytochrome
Cytochrome P-450 CYP3A5- Cytochrome P-450 CYP3A5
- Cytochrome P 450 CYP3A5
- P-450 CYP3A5, Cytochrome
- CYP3A5
- Cytochrome P450 3A5
- 3A5, Cytochrome P450
- P450 3A5, Cytochrome
Cytochrome P-450 CYP3A4- Cytochrome P-450 CYP3A4
- Cytochrome P 450 CYP3A4
- P-450 CYP3A4, Cytochrome
- Cytochrome P450 3A4
- Taurochenodeoxycholate 6-alpha-Monooxygenase
- 6-alpha-Monooxygenase, Taurochenodeoxycholate
- Taurochenodeoxycholate 6 alpha Monooxygenase
- CYP3A4
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A" by people in this website by year, and whether "Cytochrome P-450 CYP3A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 3 | 3 |
| 2008 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP3A" by people in Profiles.
-
Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients. Clin Transplant. 2018 08; 32(8):e13332.
-
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983.
-
Daikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawal. Pharmacol Res Perspect. 2017 10; 5(5).
-
Alterations of Hepatic Metabolism in Chronic Kidney Disease via D-box-binding Protein Aggravate the Renal Dysfunction. J Biol Chem. 2016 Mar 04; 291(10):4913-27.
-
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica. 2015; 45(11):990-8.
-
Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms. Drug Metab Dispos. 2015 Jul; 43(7):1084-90.
-
Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4.
-
DNA sequence-dependent compartmentalization and silencing of chromatin at the nuclear lamina. Cell. 2012 Jun 22; 149(7):1474-87.
-
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec; 70(6):854-69.
-
The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol. 2010 Jan; 6(1):17-28.